Psychiatric News (5/3) reports, “There is still not enough evidence to support the use of pharmacogenetic tests in the treatment of depression, according to updated recommendations from APA’s Workgroup on Biomarkers and Novel Treatments.” For the recommendations published in AJP in Advance, “the workgroup examined data from 11 pharmacogenetic clinical trials conducted between 2017 and 2022, as well as six meta-analyses that combined individual results.” Workgroup members wrote in the updated recommendations, “Despite expert opinions, warnings, and policy statements regarding their limitations for predicting antidepressant treatment response, the popularity of [pharmacogenetic] testing products has grown, with at least 35 U.S. commercial entities providing them by 2020.”
Related Links:
— “Evidence Base for Pharmacogenetic Tests Still Lacking, APA Workgroup Finds, Psychiatric News, May 3, 2024